Immunovia AB (publ) (IMMNOs)
Market Closed
CBOE 
- Market Cap
- P/E Ratio
- Div Yield
- Volume
- Eps
Want to track IMMNOs and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
IMMNOs is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2026, exceeded the consensus estimates by 0.0311%. On average, the company has surpassed earnings expectations by 0.0204%, based on the last three reports.
Immunovia AB (publ) has completed 1 stock splits, with the recent split occurring on Feb 03, 2026.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on XSTO (SEK).
Immunovia AB (publ) (IMMNOs) FAQ
On which exchange is it traded?
Immunovia AB (publ) is listed on CBOE.
What is its stock symbol?
The ticker symbol is IMMNOs.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Immunovia AB (publ) ever had a stock split?
Immunovia AB (publ) had 1 splits and the recent split was on Feb 03, 2026.
Immunovia AB (publ) Profile
| Professional Services Industry | Industrials Sector | Jeff Borcherding CEO | CBOE Exchange | SE0006091997 ISIN |
| SE Country | 9 Employees | - Last Dividend | 3 Feb 2026 Last Split | - IPO Date |
Overview
Immunovia AB (publ) is a pioneering diagnostic company that focuses on the development and commercialization of advanced blood-based diagnostics for cancer. Founded in 2007 and having its headquarters in Lund, Sweden, the company has made significant strides in providing innovative solutions not only within Sweden but also on a global scale. Immunovia’s mission revolves around the early detection of cancer, which is crucial for improving patient survival rates and outcomes. By leveraging cutting-edge research and technologies, the company aims to fill the gap in early cancer detection and contribute to the global fight against this life-threatening disease.
Products and Services
Immunovia’s portfolio primarily includes:
- IMMray PanCan-d: This is Immunovia’s flagship product, a blood-based test designed for the early detection of pancreatic cancer. The IMMray PanCan-d test utilizes a unique biomarker signature that can identify pancreatic cancer at an early stage, thereby potentially increasing the survival rates for patients diagnosed with this aggressive form of cancer. By offering a non-invasive and highly specific test, Immunovia addresses the critical need for early diagnosis in pancreatic cancer, which often presents with nonspecific symptoms and is typically diagnosed at an advanced stage.
Contact Information
Address: Medicon Village
Phone: 46 4 62 75 60 00
Website: https://www.immunovia.com
